Signatory of DORA
https://doi.org/10.56183/iberojhr.v4i1.623
Ibero-American Journal of Health Science Research
OPEN ACCESS
BY-NC-ND
Received: 28/04/2024
Accepted: 29/05/2024
Published: 04/06/2024

Effectiveness of Biologic Therapy in Controlling Inflammation and Achieving Disease Remission in Patients with Rheumatoid Arthritis: A Systematic Review

Josselin Alejandra Villacrés Vega
https://orcid.org/0009-0000-7441-6517
Medical Doctor, Professor at Universidad Nacional de Chimborazo, Ecuador
Correspondence: jossvi25@gmail.com

Lisbeth Paola Guamán Punguil
https://orcid.org/0009-0005-3138-6975
Independent Investigator, Ecuador

Sergio Andres Maila Zuñiga
https://orcid.org/0009-0005-2367-8142
Medical Doctor, Independent Investigator, Ecuador

Isamar Pamela Castro Lahuasi
https://orcid.org/0009-0006-9517-6667
Master´s Degree in Occupational Health and Safety, Ecuador

Angelica Marina Basantes Castillo
https://orcid.org/0009-0002-5543-1281
Medical Doctor, Ministerio de Salud Pública, Ecuador

Gabriela Rebeca Yanez García
https://orcid.org/0009-0001-9290-700X
Master´s Degree in Occupational Health and Safety, Ecuador

Nathaly Marie Yepez Alcivar
https://orcid.org/0009-0008-7753-8876
Medical Doctor, Universidad de las Américas, Ecuador

ABSTRACT

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder characterized by joint pain, swelling, and potential systemic complications. The usefulness of biological treatments in reducing inflammation and helping RA patients achieve clinical remission is assessed in this systematic narrative review. Using PubMed, Scopus, and Google Scholar, a thorough literature search was carried out with an emphasis on research published in the last five years. The inclusion criteria were English-language human subject research that contributed significantly to our understanding of biological therapies for RA. Despite concerns over long-term drug withdrawal, TNF-alpha inhibitors, including certolizumab, adalimumab, and infliximab, have shown considerable effectiveness in lowering disease activity and inducing remission. Tocilizumab and other IL inhibitors have shown strong anti-inflammatory properties and increased rates of medication retention. Certain patient profiles have shown success with other biologics, such as rituximab and abatacept, especially those who have not responded to previous therapies. Empirical evidence demonstrates that tofacitinib, a JAK inhibitor, is just as effective as conventional biologics. The study emphasizes how important it is to create individualized treatment programs depending on the medical history and response to the condition. Even with encouraging findings, improving RA care requires ongoing observation of safety profiles and long-term effects. This study offers a thorough synthesis of the available data to help physicians choose the best biologic therapy for patients with RA.

Keywords: Rheumatoid arthritis; Biologic Therapy; inflammation control.

INTRODUCTION

Since joint damage is seldom evident in the early stages of the disease, rheumatoid arthritis (RA) is a multi-etiologic, autoimmune, chronic inflammatory illness that is characterized by pain, swelling, stiffness in the morning, and symmetrical

involvement of numerous peripheral joints (Littlejohn & Monrad, 2018). In the latter stages of the illness, serositis, vasculitis, Felty's syndrome, peripheral neuropathy, and lung involvement are common extra-articular symptoms of systemic rheumatoid arthritis (RA). While there is evidence that RA existed as early as 1500 BC and that the illness was present in Egyptian mummies, the first report on RA was published in 1800 by the French Surgeon Augustin Jacob Landre-Beauvais, thereby designating RA as the modern era's disease (Entezami et al., 2011).

According to the Global Burden of Disease 2010 Study, the prevalence of RA is around 0.24% globally (Cross et al., 2014). RA is more common in North America, Australia, and other areas with European ancestry, as well as Western and Northern Europe. In East Asia and Africa, the frequency is considerably lower than it is in Central and South America (Cross et al., 2014). In the US and other western northern European countries, the yearly incidence of RA is around 40 per 100,000 people (Myasoedova et al., 2010). Based on epidemiologic data, women are more likely than men to get RA; women have a 3.6% lifetime risk of RA, while men's risk is 1.7% (Crowson et al., 2011). The risk of RA also rises with age, peaking between 65 and 80 years of age. A comprehensive analysis of 60 population-based research revealed a 0.51% global prevalence of RA throughout the 1955–2015 timeframe (Almutairi et al., 2021).

According to scientific evidence, RA results from a combination of environmental and inherited variables, with the majority of risk factors being associated with hormones, smoking, positive family history, and gene polymorphisms (PTNP22) (Deane et al., 2017). With later involvement of the wrist and knee, RA mostly affects the metacarpophalangeal, metatarsophalangeal, and proximal interphalangeal joints (Stanford & Bottini, 2014). In terms of clinical manifestations, RA is characterized by swelling, stiffness in the morning, and restricted movement of the joints. As the illness progresses, immobility and painful deformities may arise. In keeping with the disease's progressive character, rheumatoid arthritis (RA) often affects the cervical spine and temporomandibular joint in addition to serious systemic side effects such arrhythmias, septic infections, miliary TB, and mononeuritis multiplex linked to vasculitis. Joint soreness is detected during physical examination, and the presence of anti-cyclic citrullinated peptide antibody (anti-CCP Ab) and rheumatoid factor confirms the diagnosis. Levels of inflammatory markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are measured as part of an additional radiographic examination and synovial fluid analysis as part of the workup for RA (Vander Cruyssen et al., 2007).

NSAIDs and glucocorticoids are two examples of pharmaceuticals that have been found to reduce RA-related pain and inflammation, even though disease-modifying antirheumatic drugs (DMARDs) are still thought to be the first line of therapy (Abbasi et al., 2019). To mitigate the inflammatory effects of cytokines and ultimately lessen the severity of the illness, biologics are essential. These include pegylated and humanized monoclonal Abs, anti-IL-6 receptor antagonists, chimeric monoclonal antibodies (Abs) targeting CD20, and tumor necrosis factor (TNF)-alpha inhibitors. However, the patient's profile and the way the illness responded to prior treatment greatly influence the role biologics play in controlling RA. The purpose of this review article is to investigate how biologics may be used to treat RA in a way that lessens disease severity and improves prognosis.

METHODOLOGY

An integrated approach was used in this thorough analysis to carefully gather and evaluate relevant information from reputable academic sources, including PubMed, Scopus, and Google Scholar. We modified conventional protocols from previous systematic reviews to accommodate for the intricacy of the topic regarding the efficacy of biological treatment in reducing inflammation and bringing patients with rheumatoid arthritis (RA) into remission. This was done to guarantee a comprehensive analysis. To locate pertinent studies, search phrases including "biologic therapy," "rheumatoid arthritis," "inflammation control," and "disease remission" were employed.

Inclusion and Exclusion Criteria:

Papers that addressed the use of biologic treatments for RA were judged appropriate for inclusion in this review. We only took into account publications that were published in English within the preceding ten years (2013–2023) in order to represent recent developments in the field. Included were human subject studies that made a substantial contribution to our knowledge of the effectiveness of biologic treatments for RA. On the other hand, research that did not directly address the topic or that did not adhere to a suitable technique were disregarded. Using abstracts and titles, each identified article was

carefully examined to ensure that it was relevant and suitable for inclusion.

Categorization and Analysis:

A systematic categorization technique was used to organize and evaluate the heterogeneous literature on biologic treatments for RA. This review's main goals were to appraise the safety profiles of different biologic medicines and determine how well they work in lowering inflammation and establishing disease remission. To study various biologic medications, such as TNF-alpha inhibitors, IL inhibitors, and other biologics including rituximab and abatacept, analytical categories were developed. Important factors such the effectiveness of the therapy, disease activity scores (DAS), medication retention rates, and the frequency of side effects were investigated. This organized classification made it easier to analyze these biologic drugs' mechanisms of action, clinical efficacy, and safety in-depth, emphasizing the effects they have on patient outcomes and disease management.

Figure 1. Prisma



Source: the authors

RESULTS AND DISCUSSION

Role of TNF-alpha inhibitors:

The usage of TNF-alpha inhibitors has skyrocketed in the last several decades. According to a study by Radner and Aletaha, RA treatment has changed over the past few decades due to the introduction of new medications that have shown promise, including infliximab, adalimumab, certolizumab, abatacept, and golimumab (Radner & Aletaha, 2015). These

medications involve taking specific actions to limit the disease's activity.

TNF-alpha inhibitors and other new-age medications have revolutionized the treatment of RA by regulating the disease activity and reducing its development, according to research by Radner and Aletaha (Radner & Aletaha, 2015). TNF-alpha inhibitors are among the many medications that have been tried to bring RA into remission; nevertheless, there is growing discussion and worry about stopping the medication after remission is reached.

Infliximab was initially administered to RA patients in the trial by Radner and Aletaha (Radner & Aletaha, 2015). Intravenous (IV) infliximab is administered every four to eight weeks and is a chimeric monoclonal antibody (Ab) with a half-life of eight to ten days that inhibits the cytokine that activates the TNF receptor complex (You et al., 2021). As is well known, TNF-alpha triggers acute phase responses and systemic inflammation by generating neutrophils, macrophages, natural killer (NK) cells, CD4 + lymphocytes, and so forth. TNF-alpha, which triggers several physiological reactions including the release of more adhesion molecules, the activation of pro-inflammatory cytokines, and the acceleration of leukocyte migration from blood arteries into tissue, is highly affinity-bound for infliximab (You et al., 2021). It has been demonstrated that infliximab reduces the physiological consequences linked to TNF-alpha. These consequences primarily consist of heightened systemic inflammation, elevated adhesion molecules, pro-inflammatory cytokine induction, increased leukocyte migration into tissues, and diffused acute phase reaction activation.

The real-world evidence for treatment efficacy, treatment persistence, and treatment habits among community-dwelling patients treated with tofacitinib, a JAK inhibitor, for rheumatoid arthritis was examined by Paul Bird et al (Bird et al., 2020). After 2810 patients had their data collected, 1950 patients (1300 bDMARD initiators and 650 tofacitinib initiators) were included in the matched population. Patients were mostly female (81.2%) and between the ages of 55 and 74 (57.8%). In the bDMARD and tofacitinib groups, after 18 months of therapy, 52.4% and 57.8% of patients had achieved disease activity score (DAS) remission, respectively. Tofacitinib's median treatment persistence was 34.2 months (95% CI 32.2 to not attained) for bDMARDs and 33.8 months (95% CI 28.8 to 40.4) for tofacitinib. In comparison to bDMARD monotherapy (33.4%), tofacitinib monotherapy was given to a greater number of patients (43.4%) in the whole population. Tofacitinib showed comparable therapeutic efficacy and durability to bDMARDs. Overall, tofacitinib was being used more often as monotherapy than bDMARDs.

In a real-world cohort trial, Choi et al, (Choi et al., 2021) assessed the relationship between drug survival and the use of tofacitinib with first-, second-, and third-line biologic disease-modifying antirheumatic medications (bDMARDs) in seropositive rheumatoid arthritis (RA) patients. The likelihood of medication failure was examined about a number of first-, second-, and third-line therapies, including non-TNFi drugs (tocilizumab, rituximab, tofacitinib, abatacept) and TNF inhibitors (etanercept, infliximab, adalimumab, golimumab). Their results showed that, with adjusted hazard ratios (aHR) of 0.56, 0.27, and 0.83 for tocilizumab, tofacitinib, or abatacept, respectively, first-line usage was linked to a considerably decreased probability of medication failure compared to etanercept. In a similar vein, second-line usage of abatacept (aHR 0.54), tofacitinib (aHR 0.23), or tocilizumab (aHR 0.38), likewise showed a lower likelihood of medication failure. Interestingly, compared to third-line TNFi users, third-line users of tocilizumab (aHR 0.32) or tofacitinib (aHR 0.35) had the lowest incidence of medication failure. According to the study's findings, giving seropositive RA patients tocilizumab or tofacitinib as first, second, or third-line treatment may improve drug survival and lower failure rates. The AWARE research, carried out by Curtis et al, compared the clinical efficacy and incidence of infusion responses between intravenous golimumab and infliximab in patients with rheumatoid arthritis (RA) in a real-world context (Curtis et al., 2021). Infusion reactions, which are defined as any adverse event that occurs during or within an hour of infusion, were the primary endpoint of the study. Major secondary endpoints included mean change from baseline in the Clinical Disease Activity Index (CDAI) at months 6 and 12 among patients who had not yet received biologics. Formal interim analysis results showed a significantly lower incidence of infusion reactions with golimumab-IV (3.6%) compared to infliximab (17.6%, $p<0.001$), adjusted using propensity scores with inverse probability of treatment weights (IPTW). The analysis included 479 patients on golimumab-IV and 354 on infliximab. Additionally, among patients who had not yet received a biologic, the mean changes in CDAI from baseline at months 6 and 12 showed that golimumab-IV was not inferior to infliximab. The changes were -9.5 vs. -10.1 at month 6 and -9.4 vs. -10.1 at month 12, respectively. The research found no further advantages from infliximab dosage escalation in terms of CDAI improvements for RA patients, and that golimumab-IV had a considerably reduced incidence of infusion reactions and non-inferior clinical efficacy compared to infliximab.

Using actual data from the IBM MarketScan Commercial Claims and Encounters Database, Gharaibeh et al. (2020) carried out a retrospective analysis to assess the costs and efficacy of targeted immunomodulators (TIMs) in the treatment of moderate to severe rheumatoid arthritis (RA) (Gharaibeh et al., 2020). 14,775 patients who were administered different TIMs, including abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, tocilizumab, and tofacitinib, were included in the research. First- and second-line TIM treatments showed varying levels of effectiveness: abatacept (27.1%, 18.1%), adalimumab (30.9%, 22.1%), certolizumab pegol (20.9%, 14.3%), etanercept (31.4%, 31.5%), golimumab (32.7%,

22.2%), infliximab (21.9%, 21.3%), tocilizumab (30.9%, 30.6%), and tofacitinib (26.0%, 21.6%). The results of the research showed that adherence had a major role in efficacy, with non-effectiveness often stemming from a failure to reach an 80% medication possession ratio. Adalimumab is a monoclonal antibody of recombinant IgG that works against TNF-alpha, suppresses cytokine-induced inflammation, is physiologically similar to human IgG, and has a low potential for immunogenicity (Patel, Konanur Srinivasa, et al., 2023). By stimulating NF-kappa B receptors on stromal and osteoblast cells, it stops the deterioration of bone and cartilage.

To compare the safety and effectiveness of tocilizumab, sarilumab, and sirukumab as monotherapy versus adalimumab in patients with active rheumatoid arthritis (RA) who were intolerant of or did not respond well to methotrexate (MTX), Sung and Lee (2020) performed a Bayesian network meta-analysis (Sung & Lee, 2021). The inclusion criteria were satisfied by three RCTs with 1,066 participants. For the ACR20 response rate, tocilizumab 8 mg monotherapy had the most advantageous surface under the cumulative ranking curve (SUCRA). When used in monotherapy, tocilizumab, sarilumab, and adalimumab had significantly greater ACR20 response rates. Tocilizumab 8 mg was shown to have the greatest ranking likelihood based on SUCRA, making it the best option for reaching ACR20 response rate. Sarlumab 200 mg, adalimumab 40 mg, and sirukumab 50 mg were the next best options. Furthermore, the distribution pattern of the ACR50 response rate was comparable to that of the ACR20. Based on SUCRA, the ranking likelihood for adverse events suggested that sirukumab 50 mg, adalimumab 40 mg, tocilizumab 8 mg, and sarilumab 200 mg could be the least harmful. Nonetheless, there was no discernible difference in the proportion of patients who encountered severe side effects between these biologics.

Rahman et al, assessed the long-term efficacy and safety of infliximab (IFX), golimumab (GLM), and intravenous golimumab (GLM-IV) in patients with rheumatoid arthritis (RA) in Canada using a prospective observational trial that used data from the BioTRAC registry (Rahman et al., 2020). The percentage of female patients among the 890 IFX-, 530 GLM-, and 157 GLM-IV-treated patients varied from 77.0 to 86.6%, with mean ages ranging from 55.8 to 57.7 and mean illness durations from 6.5 to 8.6 years. Over time, there was a discernible decline in the baseline duration of the illness and the disease activity indicators (DAS, TJC, SJC, HAQ, AM stiffness, MDGA, PtGA, CRP, and ESR). Over time, treatment with IFX, GLM-, and GLM-IV markedly improved all illness indicators. For IFX, GLM, and GLM-IV treated patients, the incidence of AEs was 105, 113, and 82.6 /100 PYs, while the incidence of SAEs was 11.7, 11.2, and 4.68 /100 PYs. As a result, every therapy lowered the disease's activity considerably and increased functioning in a comparable way. The frequency of adverse events matched both IFX and GLM's safety profiles.

In order to investigate the drug retention rates and reasons for stopping seven biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF) among patients with biologic-naïve and biologic-switched rheumatoid arthritis (RA), Ebina et al, carried out a thorough multi-center retrospective study within the ANSWER cohort. 4,415 treatment courses were examined in the research, including 2,737 bDMARD-naïve and 1,678 bDMARD-switched individuals (Ebina, Hirano, Maeda, Yamamoto, Yamamoto, et al., 2020). Significant differences were seen by the researchers in the reasons for medication cessation across the various therapies, including ineffectiveness, hazardous side effects, and remission. The percentage of patients who stopped taking their medications because they weren't working varied from 13.7% for abatacept (ABT) to 26.9% for certolizumab pegol (CZP) in biologic-naïve patients to 18.9% for tocilizumab (TCZ) in biologic-switched individuals. In patients who had not converted to biologics, the percentage of patients who discontinued owing to toxic side events ranged from 5.0% for etanercept (ETN) to 11.2% for ABT, and from 4.6% to 15.7% for TOF. In patients who had not switched to biologics, the incidence of discontinuation owing to remission was greatest for infliximab (IFX) at 10.0%, whereas CZP and golimumab (GLM) ranged from 1.1% to 3.3%. These results highlight how crucial it is to manage RA treatment regimens by taking the patient's history and medication features into account.

By merging 20 previous studies, research was carried out over one year in a sample group of 346 RA patients, using observational and interventional study designs (Ursini et al., 2017). Based on the medications prescribed to each patient, the groups were as follows: 61 patients received infliximab, 122 received adalimumab, 82 received etanercept, and 81 received any combination of the aforementioned three for which there was no particular data available as of yet. After reviewing these trials, Ursini et al. concluded that patients receiving TNF-alpha inhibitors had improved cardiovascular system (CVS) and endothelial function, along with a reduction in atherosclerosis and arterial wall stiffness. It was determined that to alleviate the constraints and acquire more solid findings, a bigger sample population and a prolonged observation time would be necessary due to the difficulty of conducting comprehensive research.

Linked to polyethylene glycol (PEG), certolizumab is a humanized monovalent Fab Ab fragment that functions differently from previous TNF inhibitors (Radner & Aletaha, 2015). The PEG component is a large, hydrophilic inert molecule that lengthens the drug's estimated two-week plasma half-life. The recommended adult dose is 400 mg, administered as two 200 mg subcutaneous injections at the beginning of the medication and at weeks two and four, then 200 mg every other week.

Role of IL inhibitors:

An IL-1one inhibitor called anakinra helps to simulate the course of the illness and enhance the blocking of IL receptors. Until November 2017, Nikfar et al. examined clinical trials and extension studies using resources including PubMed, Scopus, and Web of Science to assess the efficacy and safety of the medicine (Nikfar et al., 2018). The effectiveness outcome measure used in the review was the ACR20, and around ten trials were included in total. Anakinra-treated patients had a 42% chance of an ACR20 response, including a substantial drop in ESR and HAQ scores, despite a 34% risk of treatment discontinuation linked with the drug. A pro-inflammatory cytokine, IL-6 binds to receptors and triggers intracellular signaling pathways that impact osteoclast activation, cytokine production, and the acute phase response. These pathways also negatively impact joint inflammation and the course of the illness (Patel, Konanur Srinivasa, et al., 2023). Tocilizumab, a humanised monoclonal antibody, inhibits the synthesis of cytokines and is linked to an increased risk of pancytopenia, infection, and atherosclerosis. It targets both the soluble and membrane versions of IL-6 receptors.

In patients with rheumatoid arthritis (RA) following the use of at least one biologic disease-modifying antirheumatic drug (bDMARD), Kim Lauper et al. compared the efficacy of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibitors (TNFi) as monotherapy or in combination with conventional synthetic DMARDs (Lauper et al., 2018). We were able to collect data from 771 patients receiving TCZ monotherapy, 1773 patients receiving combination treatment, 1404 patients receiving TNFi monotherapy, and 4660 patients receiving TNFi combo therapy. TCZ combo (1.98 years, 95% CI 1.83 to 2.11) and TCZ mono (2.31 years, 95% CI 2.07 to 2.61) had crude median retentions greater than TNFi combo (1.37 years, 95% CI 1.30 to 1.45) and TNFi mono (1.31 years, 95% CI 1.18 to 1.47). In a covariate-adjusted, country- and year-stratified study, the discontinuation risks were comparable for patients on TCZ mono and combo, but considerably lower for patients on TNFi mono and combo, and TNFi combo compared with TNFi mono. The average adjusted CDAI change was comparable throughout the groups. Comparable rates of LDA and CDAI remission were seen across the groups.TCZ mono or combo are appropriate treatment choices in patients who do not respond well to at least one bDMARD, because of their much longer drug retention and comparable effectiveness to TNFi combination.

Other biologics:

Ustekinumab is a human monoclonal antibody that suppresses the action of illness by blocking cytokines, including IL-12 and IL-23. By preventing T-cell co-stimulation and enhancing the functional impairment linked to RA, the fusion protein abatacept has shown a promising effect in lowering disease activity and improving radiographic progression (Littlejohn & Monrad, 2018). Since it takes longer to take effect and has been linked to a higher risk of infection, it is mostly used in conjunction with other medicines. Apart from that, it is often well tolerated. Rituximab, a chimeric monoclonal antibody that targets CD20, is primarily expressed by mature B-lymphocytes. It is approved to treat refractory RA in conjunction with MTX, where it exhibits improved tolerance with seropositive disease, which has been linked to an increased risk of infection, including progressive multifocal leukoencephalopathy (Littlejohn & Monrad, 2018).

In Spain, 75 patients with RA and 90 healthy control patients were engaged in a three-month cohort study by Perez-Sanchez et al, Furthermore, a study involving 16 patients was carried out to investigate the impact of rituximab (a CD20 inhibitor) on the immune system and its potential to slow the advancement of the illness (Pérez-Sánchez et al., 2019). The study's final data collection showed that rituximab was effective in reducing the proportion of B-cells and cytokines in RA [34]. The evaluation of the study was based on B-cells and pro-inflammatory cytokines, and the tests employed were flow cytometry and reverse transcription polymerase chain reaction (RT-PCR). The results were sufficient to support the idea that rituximab therapy administered early on resets the balance of cytokines in the immune system and vascular wall.

According to some research, TNF-alpha medicines may reactivate the cytomegalovirus (CMV) when used with immunosuppressive treatments (Patel, Konanur Srinivasa, et al., 2023). Rarely, reactivation of the Epstein-Barr virus (EBV) and other herpes viruses has also been reported in conjunction with abatacept. However, it is unclear if these cases are the result of prior or concurrent immunosuppression, as another study shows that long-term abatacept use does not affect the immune system's ability to control EBV infection. Over time, anti-drug antibodies may form against the medications infliximab and adalimumab (Kawabe et al., 2019).

Discussion:

The systematic narrative review's findings demonstrate the significant advancements in biological therapy for rheumatoid arthritis (RA), emphasizing the latter's capacity to reduce inflammation and induce a state of disease remission. Numerous biologics, such as IL inhibitors, TNF-alpha inhibitors, and others, have shown great promise in controlling the signs and symptoms of RA. In the last several years, TNF-alpha inhibitors have completely changed the way that RA is treated. Examples of these include golimumab, certolizumab, adalimumab, abatacept, and infliximab. These inhibitors are a key component of RA care because they have dramatically decreased disease activity and development as demonstrated by many researchers. The real-world data reported by Bird et al, suggests that there is still disagreement on whether to continue these drugs after remission is reached (Bird et al., 2020). After 18 months of medication, 52.4% and 57.8% of patients in the bDMARD and tofacitinib groups, respectively, achieved disease activity score (DAS) remission, demonstrating the same

therapeutic effectiveness and durability of tofacitinib compared to bDMARDs.

In addition, Choi et al.'s research showed that in comparison to TNF inhibitors like etanercept, tocilizumab and tofacitinib as first-, second-, and third-line therapy dramatically decreased the chance of drug failure (Choi et al., 2021). This implies that for certain patients, especially those with seropositive RA, these more recent biologics may provide longer-lasting benefits. Curtis et al.'s AWARE study from 2021 offered further information, demonstrating that intravenous golimumab had a much lower incidence of infusion reactions than infliximab while maintaining non-inferior clinical efficacy (Curtis et al., 2021). This finding underscores the significance of taking safety and efficacy into account when making treatment decisions.

Adherence to drug regimens is crucial, as shown by cost and effectiveness evaluations like the one carried out by Gharaibeh et al, (Gharaibeh et al., 2020). According to their research, adherence played a significant role in the efficiency of targeted immunomodulators (TIMs), and non-effectiveness was often associated with a failure to reach an 80% medication possession ratio. This highlights the need of devising tactics to enhance patients' compliance with biologic medicines in order to optimize their advantages. As Patel et al, describe, adalimumab, another popular TNF-alpha inhibitor, has shown remarkable efficacy in inhibiting cytokine-induced inflammation and maintaining bone and cartilage integrity (Patel, Srinivasa, et al., 2023). Sung and Lee conducted a Bayesian network meta-analysis which revealed that tocilizumab monotherapy had the highest favorable surface under the cumulative ranking curve (SUCRA) for the ACR20 response rate. This indicates that it is a highly efficacious treatment option for patients who are intolerant or unresponsive to methotrexate (MTX) (Sung & Lee, 2021).

Long-term research has shown that infliximab, golimumab, and intravenous golimumab are safe and effective treatments for RA patients in Canada. One such study is the prospective observational trial conducted by Rahman et al, (Rahman et al., 2020). Further supporting their usage in long-term RA care, these therapies were well-tolerated and over time showed considerable improvements in disease activity markers. Ebina et al, also emphasized the need to take a patient history and pharmaceutical features into account while managing treatment regimens for RA, pointing out notable variations in drug retention rates and reasons for discontinuation across different biologics (Ebina, Hirano, Maeda, Yamamoto, Hashimoto, et al., 2020). By showing that TNF-alpha treatments enhanced endothelial and cardiovascular function and decreased atherosclerotic and arterial wall stiffness in patients with RA, Ursini et al, expanded the body of data. Taking into account the elevated cardiovascular risk linked to RA, this cardiovascular benefit is essential (Ursini et al., 2017).

RA symptoms have also been shown to be well controlled with IL inhibitors, including anakinra and tocilizumab. Anakinra-treated patients had a considerable likelihood of obtaining an ACR20 response, but there was also a large risk of stopping therapy, according to Nikfar et al, (Nikfar et al., 2018). As opposed to this, tocilizumab targets IL-6 receptors and has been associated with significant decreases in joint inflammation and disease progression, along with a lower chance of side effects such as infection and pancytopenia (Patel, Konanur Srinivasa, et al., 2023).

Additional alternatives for managing RA have been made possible by other biologics, including rituximab, abatacept, and ustekinumab. Rituximab targets CD20 on B-lymphocytes, while abatacept prevents T-cell co-stimulation, and uzekinumab targets IL-12 and IL-23. These biologics may successfully lower disease activity and improve radiographic progression, despite a range of risks and adverse effects, as studies by Littlejohn and Monrad and Pérez-Sánchez et al, have shown (Pérez-Sánchez et al., 2019)(Littlejohn & Monrad, 2018).

CONCLUSION

In conclusion, biologic treatments have significantly improved patient quality of life and disease control while also marking a substantial advancement in the therapy of rheumatoid arthritis. While long-term discontinuation and safety issues persist, TNF-alpha inhibitors, IL inhibitors, and other biologics like rituximab and abatacept have shown significant effectiveness in decreasing inflammation and attaining remission. Optimizing results requires personalized treatment methods that are informed by real-world data and patient-specific characteristics. Furthermore, newer treatments such as JAK inhibitors have similar effectiveness to established biologics, broadening the range of available treatments. To improve these therapies and guarantee long-term benefits for RA patients, ongoing research and careful observation of long-term effects are essential.

Biologic treatments have many drawbacks when it comes to treating rheumatoid arthritis. These include their expensive cost, which may prevent them from being widely accessible, and their potential for major side effects, such an increased risk of infections and cancers. Furthermore, even though biologics have shown a great deal of success, patient response varies widely, and a sizable percentage of patients may not get a lasting remission. There are currently insufficient long-term safety data, thus ongoing observation is required to spot any delayed negative consequences. Furthermore, stopping biologic therapy often results in a return of the illness, underscoring the necessity for continued care and the

difficulty of attaining a long-lasting remission.

Prospects for the future of biologic therapy-assisted rheumatoid arthritis care include the creation of more individualized and focused treatment plans. Developments in biomarkers and genetics may help drive customized treatment regimens and improve patient response prediction. Combination therapy, such as the use of biologics in conjunction with JAK inhibitors or other small molecule inhibitors, have the potential to improve effectiveness while reducing side effects. Furthermore, in order to guarantee a greater benefit to patients, efforts must be made to make these therapies more accessible and affordable. To maximize the utilization of novel and current medicines in clinical practice and to get a deeper understanding of their safety profiles, it will be essential to maintain funding for long-term research.

REFERENCES

1. Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019). Strategies toward rheumatoid arthritis therapy; the old and the new. *Journal of Cellular Physiology*, *234*(7), 10018–10031. https://doi.org/10.1002/JCP.27860
2. Almutairi, K. B., Nossent, J. C., Preen, D. B., Keen, H. I., & Inderjeeth, C. A. (2021). The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies. *The Journal of Rheumatology*, *48*(5), 669–676. https://doi.org/10.3899/JRHEUM.200367
3. Bird, P., Littlejohn, G., Butcher, B., Smith, T., da Fonseca Pereira, C., Witcombe, D., & Griffiths, H. (2020). Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. *Clinical Rheumatology*, *39*(9), 2545–2551. https://doi.org/10.1007/S10067-020-05021-7
4. Choi, S., Ghang, B., Jeong, S., Choi, D., Lee, J. S., Park, S. M., & Lee, E. Y. (2021). Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting. *Seminars in Arthritis and Rheumatism*, *51*(4), 685–691. https://doi.org/10.1016/J.SEMARTHRIT.2021.06.002
5. Cross, M., Smith, E., Hoy, D., Carmona, L., Wolfe, F., Vos, T., Williams, B., Gabriel, S., Lassere, M., Johns, N., Buchbinder, R., Woolf, A., & March, L. (2014). The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Annals of the Rheumatic Diseases*, *73*(7), 1316–1322. https://doi.org/10.1136/ANNRHEUMDIS-2013-204627
6. Crowson, C. S., Matteson, E. L., Myasoedova, E., Michet, C. J., Ernste, F. C., Warrington, K. J., Davis, J. M., Hunder, G. G., Therneau, T. M., & Gabriel, S. E. (2011). The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. *Arthritis and Rheumatism*, *63*(3), 633–639. https://doi.org/10.1002/ART.30155
7. Curtis, J. R., Chakravarty, S. D., Black, S., Kafka, S., Xu, S., Langholff, W., Parenti, D., Greenspan, A., & Schwartzman, S. (2021). Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study. *Rheumatology and Therapy*, *8*(4), 1551–1563. https://doi.org/10.1007/S40744-021-00354-4
8. Deane, K. D., Demoruelle, M. K., Kelmenson, L. B., Kuhn, K. A., Norris, J. M., & Holers, V. M. (2017). Genetic and environmental risk factors for rheumatoid arthritis. *Best Practice & Research Clinical Rheumatology*, *31*(1), 3–18. https://doi.org/10.1016/J.BERH.2017.08.003
9. Ebina, K., Hirano, T., Maeda, Y., Yamamoto, W., Hashimoto, M., Murata, K., Takeuchi, T., Nagai, K., Son, Y., Amuro, H., Onishi, A., Jinno, S., Hara, R., Katayama, M., Yamamoto, K., Kumanogoh, A., & Hirao, M. (2020). Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-. *Clinical Rheumatology*, *39*(9), 2563–2572. https://doi.org/10.1007/S10067-020-05015-5
10. Ebina, K., Hirano, T., Maeda, Y., Yamamoto, W., Yamamoto, W., Hashimoto, M., Murata, K., Takeuchi, T., Shiba, H., Son, Y., Amuro, H., Onishi, A., Akashi, K., Hara, R., Katayama, M., Yamamoto, K., Kumanogoh, A., & Hirao, M. (2020). Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study. *Arthritis Research and Therapy*, *22*(1). https://doi.org/10.1186/S13075-020-02232-W
11. Entezami, P., Fox, D. A., Clapham, P. J., & Chung, K. C. (2011). Historical Perspective on the Etiology of Rheumatoid Arthritis. *Hand Clinics*, *27*(1), 1–10. https://doi.org/10.1016/j.hcl.2010.09.006
12. Gharaibeh, M., Bonafede, M., McMorrow, D., Maksabedian Hernandez, E. J., & Stolshek, B. S. (2020). Effectiveness and costs among rheumatoid arthritis patients treated with targeted immunomodulators using real-world U.S. data. *Journal of Managed Care and Specialty Pharmacy*, *26*(8), 1039–1049. https://doi.org/10.18553/JMCP.2020.26.8.1039
13. Kawabe, A., Nakano, K., Miyata, H., Shibuya, R., Matsuyama, A., Ogoshi, T., & Tanaka, Y. (2019). Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. *Internal Medicine*, *58*(4), 585–591. https://doi.org/10.2169/INTERNALMEDICINE.1280-18
14. Lauper, K., Nordström, D. C., Pavelka, K., Hernández, M. V., Kvien, T. K., Kristianslund, E. K., Santos, M. J., Rotar, Ž., Iannone, F., Codreanu, C., Lukina, G., Gale, S. L., Sarsour, K., Luder, Y., Courvoisier, D. S., & Gabay, C. (2018). Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: Analyses

from the pan-European TOCERRA register collaboration. *Annals of the Rheumatic Diseases*, *77*(9), 1276–1282. https://doi.org/10.1136/ANNRHEUMDIS-2017-212845

15. Littlejohn, E. A., & Monrad, S. U. (2018). Early Diagnosis and Treatment of Rheumatoid Arthritis. *Primary Care - Clinics in Office Practice*, *45*(2), 237–255. https://doi.org/10.1016/j.pop.2018.02.010
16. Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. (2010). Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. *Arthritis and Rheumatism*, *62*(6), 1576–1582. https://doi.org/10.1002/ART.27425
17. Nikfar, S., Saiyarsarai, P., Tigabu, B. M., & Abdollahi, M. (2018). Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology International*, *38*(8), 1363–1383. https://doi.org/10.1007/S00296-018-4041-1/METRICS
18. Patel, J. P., Konanur Srinivasa, N. K., Gande, A., Anusha, M., Dar, H., & Baji, D. B. (2023). The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. *Cureus*, *15*(1). https://doi.org/10.7759/CUREUS.33293
19. Patel, J. P., Srinivasa, N. K. K., Gande, A., Anusha, M., Dar, H., & Baji, D. B. (2023). The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. *Cureus*, *15*(1). https://doi.org/10.7759/CUREUS.33293
20. Pérez-Sánchez, C., Cecchi, I., Barbarroja, N., Patiño-Trives, A. M., Luque-Tévar, M., Pérez-Sánchez, L., Ibáñez-Costa, A., Arias de la Rosa, I., Ortega, R., Escudero, A., Castro, M. C., Radin, M., Roccatello, D., Sciascia, S., Aguirre, M. Á., Collantes, E., & López-Pedrera, C. (2019). Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. *Journal of Cellular and Molecular Medicine*, *23*(9), 6308–6318. https://doi.org/10.1111/JCMM.14517
21. Radner, H., & Aletaha, D. (2015). Anti-TNF in rheumatoid arthritis: an overview. *Wiener Medizinische Wochenschrift (1946)*, *165*(1–2), 3–9. https://doi.org/10.1007/S10354-015-0344-Y
22. Rahman, P., Baer, P., Keystone, E., Choquette, D., Thorne, C., Haraoui, B., Chow, A., Faraawi, R., Olszynski, W., Kelsall, J., Rampakakis, E., Lehman, A. J., & Nantel, F. (2020). Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. *BMC Rheumatology*, *4*(1). https://doi.org/10.1186/S41927-020-00145-4
23. Stanford, S. M., & Bottini, N. (2014). PTPN22: the archetypal non-HLA autoimmunity gene. *Nature Reviews Rheumatology 2014 10:10*, *10*(10), 602–611. https://doi.org/10.1038/nrrheum.2014.109
24. Sung, Y. K., & Lee, Y. H. (2021). Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. *International Journal of Clinical Pharmacology and Therapeutics*, *59*(9), 618–626. https://doi.org/10.5414/CP204017
25. Ursini, F., Leporini, C., Bene, F., D'Angelo, S., Mauro, D., Russo, E., De Sarro, G., Olivieri, I., Pitzalis, C., Lewis, M., & Grembiale, R. D. (2017). Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. *Scientific Reports 2017 7:1*, *7*(1), 1–10. https://doi.org/10.1038/s41598-017-05759-2
26. Vander Cruyssen, B., Hoffman, I. E. A., Peene, I., Union, A., Mielants, H., Meheus, L., & De Keyser, F. (2007). Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. *Annals of the Rheumatic Diseases*, *66*(3), 364–369. https://doi.org/10.1136/ARD.2006.053470
27. You, Y., Stelzl, P., Joseph, D. N., Aldo, P. B., Maxwell, A. J., Dekel, N., Liao, A., Whirledge, S., & Mor, G. (2021). TNF-α Regulated Endometrial Stroma Secretome Promotes Trophoblast Invasion. *Frontiers in Immunology*, *12*, 737401. https://doi.org/10.3389/FIMMU.2021.737401/BIBTEX